Skip to Content

Drug interactions between Cefotan and Coumadin

Results for the following 2 drugs:
Cefotan (cefotetan)
Coumadin (warfarin)

Interactions between your drugs


warfarin ↔ cefotetan

Applies to:Coumadin (warfarin) and Cefotan (cefotetan)

Consumer information for this interaction is not currently available.

MONITOR: Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity. Decreased prothrombin activity has been reported during treatment with various cephalosporins. Risk factors include renal or hepatic impairment, poor nutritional state, protracted antimicrobial therapy, and chronic anticoagulation therapy.

MANAGEMENT: Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.


  1. Wood T, Johnson K, Naylor S, Weinshilboum R "Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia." Drug Metab Dispos 30 (2002): 1123-1128
  2. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc, Baltimore, MD.
  3. Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
  4. Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976): 91-3
  5. Chen LJ, Hsiao FY, et al "Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study." PLoS One 11 (2016): 1-11
  6. Khaleeli M, Giorgio AJ "Defective platelet function after cephalosporin administration." Blood 48 (1976): 791-2
  7. Lipsky JJ "N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia." Lancet 2 (1983): 192-3
  8. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb, Princeton, NJ.
  9. Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985): 721-2
  10. Weitekamp MR, Aber RC "Prolonged bleeding times and bleeding diathesis associated with moxalactam administration." JAMA 249 (1983): 69-71
  11. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company, Indianapolis, IN.
  12. Haubenstock A, Schmidt P, Zazgornik J, et al "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983): 1215-6
  13. Angaran DM, Dias VC, Arom KV, et al "The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient." Ann Surg 206 (1987): 155-61
  14. "Product Information. Omnicef (cefdinir)." Parke-Davis, Morris Plains, NJ.
  15. "Product Information. Keflex (cephalexin)." Dista Products Company, Indianapolis, IN.
  16. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb, Princeton, NJ.
  17. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome, Research Triangle Park, NC.
  18. Reddy J, Bailey RR "Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics." N Z Med J 92 (1980): 378-80
  19. "Product Information. Mefoxin (cefoxitin)." Merck & Co, Inc, West Point, PA.
  20. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories, Nutley, NJ.
  21. Mackie I J, Walshe K, et al "Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations." J Clin Pathol 39 (1986): 1245-1249
  22. Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974): 1324
  23. Joehl RJ, Rasbach DA, Ballard JO, et al "Moxalactam: evaluation of clinical bleeding in patients with abdominal infection." Arch Surg 118 (1983): 1259-61
  24. Bang NU, Tessler SS, Heidenreich RO, et al "Effects of moxalactam on blood coagulation and platelet function." Rev Infect Dis 4 (1982): s546-54
  25. Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988): 88-95
  26. "Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  27. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc, Deerfield, IL.
  28. "Product Information. Ancef (cefazolin)." SmithKline Beecham, Philadelphia, PA.
  29. Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984): 316
  30. Ministerio de Sanidad y Consumo. Gobierno de España "AEMPS. Agencia Española de Medicamentos y Productos Sanitarios. Available from: URL:"
  31. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn, Kalamazoo, MI.
  32. Brown RB, Klar J, Lemeshow S, et al "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986): 2159-64
  33. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  34. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb, Princeton, NJ.
  35. "Product Information. Cedax (ceftibuten)." Schering-Plough, Liberty Corner, NJ.
  36. Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr "Comparative effects of cefoxitin and cefotetan on vitamin K metabolism." Antimicrob Agents Chemother 32 (1988): 1446-9
  37. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals, St. Louis, MO.
  38. Agnelli G, Del Favero A, et al "Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?" Antimicrob Agents Chemother 29 (1986): 1108-1109
  39. Manson JM, Zolna LE, Kang YJ, Johnson CM "Effects of Cefonicid and Other Cephalosporin Antibiotics on Male Sexual Development in Rats." Antimicrob Agents Chemother 31 (1987): 991-997
  40. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
  41. Cerner Multum, Inc. "Australian Product Information." O 0
  42. Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984): 314-6
  43. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  44. Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984): 1016
View all 44 references

Drug and food interactions


warfarin food

Applies to: Coumadin (warfarin)

Nutrition and diet can affect your treatment with warfarin. Therefore, it is important to keep your vitamin supplement and food intake steady throughout treatment. For example, increasing vitamin K levels in the body can promote clotting and reduce the effectiveness of warfarin. While there is no need to avoid products that contain vitamin K, you should maintain a consistent level of consumption of these products. Foods rich in vitamin K include beef liver, broccoli, Brussels sprouts, cabbage, collard greens, endive, kale, lettuce, mustard greens, parsley, soy beans, spinach, Swiss chard, turnip greens, watercress, and other green leafy vegetables. Moderate to high levels of vitamin K are also found in other foods such as asparagus, avocados, dill pickles, green peas, green tea, canola oil, margarine, mayonnaise, olive oil, and soybean oil. However, even foods that do not contain much vitamin K may occasionally affect the action of warfarin. There are reports of patients who experienced bleeding complications and increased INR or bleeding times after consuming large quantities of cranberry juice, mangos, or pomegranate juice. Again, you do not need to avoid these foods completely, but it may be preferable to limit their consumption, or at least maintain the same level of use while you are receiving warfarin. Talk to a healthcare provider if you are uncertain about what foods or medications you take that may interact with warfarin. It is important to tell your doctor about all medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor. When warfarin is given with enteral (tube) feedings, you may interrupt the feeding for one hour before and one hour after the warfarin dose to minimize potential for interaction. Feeding formulas containing soy protein should be avoided.

Switch to professional interaction data

Therapeutic duplication warnings

No therapeutic duplications were found for your selected drugs.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.